Cosentyx Disease Interactions

Secukinumab may increase the risk of infections. There have been postmarketing reports of serious bacterial, viral, and fungal opportunistic infections; some fatal infections have been reported in patients receiving secukinumab. Cases of hepatitis B reactivation have been reported. Caution is recommended when considering the use of secukinumab in patients with a chronic infection or history of recurrent infection. A hepatitis specialist should be consulted if signs of hepatitis B virus reactivation occur; secukinumab is not recommended for use in patients with active viral hepatitis.

New onset and exacerbations of inflammatory bowel disease (IBD), in some cases serious, have been reported in patients treated with secukinumab. Caution should be used when prescribing secukinumab to patients with IBD. Patients treated with secukinumab should be monitored for signs/symptoms of IBD.

There have been postmarketing reports of active tuberculosis (TB) developing in patients with history of latent TB who were treated with secukinumab. Before starting treatment with secukinumab, patients should be evaluated for active or latent TB infection. Administration of secukinumab should be avoided in patients with active TB infection. Treatment of latent TB should be started before using secukinumab. Anti-TB therapy should be considered prior to starting secukinumab in patients with history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients should be monitored closely for signs/symptoms of active TB during and after therapy.